Use of sertraline and agomelatine in hemodialysis patients: A case series report

OBJECTIVE

Major depressive disorder (MDD) is one of the most common psychiatric issues in hemodialysis population. However, the research on proper diagnostic tools and its treatment is still insufficient. The study was performed to investigate the safety and effectiveness of sertraline and agomelatine in a group of hemodialysis patients.

PATIENTS AND METHODS

78 adult patients from one dialysis centre in Poland were included into the study. The Beck Depression Inventory II (BDI-II) was used to screen for depressive symptoms and was followed by the clinical interview with the psychiatrist. Nine patients diagnosed with major depressive disorder received antidepressant treatment with sertraline or agomelatine, according to the best clinical practice. The additional treatment with vortioxetine was used if the initial one was not effective. The time of observation was 24 weeks. The psychiatric follow up as well as the laboratory data were obtained during the course of observation.

RESULTS

All patients receiving sertraline achieved remission of depressive symptoms. In patients receiving agomelatine no remission was observed despite dose augmentation. The side effects of antidepressants were mild and did not result in treatment discontinuation. No abnormalities in liver enzymes levels were observed. In five cases the significant decrease of haemoglobin level was noticed, with no cases of bleeding reported.

CONCLUSION

In patients receiving sertraline the antidepressant effect was satisfactory. No remission of depressive symptoms was observed in patients taking agomelatine. The side effects of antidepressants were mild and transient. Further research on depression treatment in hemodialysis patients is needed, including newer medications.

Aggressive behavior and prognosis in patients with mild cognitive impairment

The diagnosis of mild cognitive impairment (MCI) is associated with an increased risk of developing dementia. When evaluating the further prognosis of MCI, the occurrence of neuropsychiatric symptoms, particularly aggressive and impulsive behavior, may play an important role.

Objective

The aim of this study was to evaluate the relationship between aggressive behavior and cognitive dysfunction in patients diagnosed with MCI.

Methods

The results are based on a 7-year prospective study. At the time of inclusion in the study, participants, recruited from an outpatient clinic, were assessed with Mini-Mental State Examination (MMSE) and the Cohen-Mansfield Agitation Inventory (CMAI). A reassessment was performed after 1 year using the MMSE scale in all patients. The time of next MMSE administration was depended on the clinical condition of patients took place at the end of follow-up, that is, at the time of diagnosis of the dementia or after 7 years from inclusion when the criteria for dementia were not met.

Results

Of the 193 patients enrolled in the study, 75 were included in the final analysis. Patients who converted to dementia during the observation period exhibited a greater severity of symptoms in each of the assessed CMAI categories. Moreover, there was a significant correlation between the global result of CMAI and the results of the physical nonaggressive and verbal aggressive subscales with cognitive decline during the first year of observation.

Conclusions

Despite several limitations to the study, aggressive and impulsive behaviors seem to be an unfavorable prognostic factor in the course of MCI.

Cognitive functions and thyroid hormones secretion disorders

The functioning of the thyroid gland is of great importance for the formation, maturation and activity of the central nervous system. The association of clinical thyroid dysfunction with mental disorders, including cognitive impairment, seems to be well documented. Abnormal concentrations of thyroid hormones can lead to deterioration of cognitive processes through changes in neurotransmission, intensification of oxidative stress, or impact on β-amyloid transformation and glucose metabolism in the central nervous system. Doubts concern mainly subclinical forms of thyroid dysfunction. According to some data, they are supposed to be related to the state of cognitive functions and to be one of the factors accelerating the mechanisms leading to degeneration of the brain tissue and, consequently, development of dementia. The results of studies on the correlation of thyroid activity with cognitive functions and the possible beneficial effects of hormonal supplementation on cognitive processes, however, bring contradictory results, which may be at least partly due to large methodological problems. One should also not exclude a reverse correlation, where the ongoing neurodegenerative process would affect thyroid function, e.g., by the changed production and secretion of thyroliberin. Despite several decades of intensive research, the explanation of this relationship is still far from conclusive.